Epithelix Sàrl 18, Chemin des Aulx – CH-1228 Plan-les-Ouates – Genève – Switzerland

Tel: +41 (0) 22 794 65 15 / Fax: +41 (0) 22 794 65 17 epithelix@epithelix.com – www.epithelix.com

Products: What’s New in 2018

3D ALI airway epithelia

long shelf-life, fully differentiated, ready-to-use

MucilAir™ (-HF) and SmallAir™ (-HF) available from:

Primary cells from single donor or “pool-of-donors”

24 or 96 well format

Different anatomical origins: Nasal, Tracheal, Bronchial and Small Airways (new)

Several pathologies:

- Normal (Controls) - Asthma

- COPD (Chronic Obstructive Pulmonary Disease) - Allergic Rhinitis

- CF (Cystic Fibrosis – several mutations available)

Epithelix Sàrl 18, Chemin des Aulx – CH-1228 Plan-les-Ouates – Genève – Switzerland

Tel: +41 (0) 22 794 65 15 / Fax: +41 (0) 22 794 65 17 epithelix@epithelix.com – www.epithelix.com

Currently available products

Human Airway Tissues

Description Ref # Description Ref #

Mu

cilA

ir™

MucilAir™ MucilAir™ Pool of Donors MucilAir™-Asthma MucilAir™-Allergic Rhinitis MucilAir™-Smoker MucilAir™-COPD MucilAir™-CF

EP01MD EP02MP EP03MD EP04MD EP05MD EP06MD EP07MD

MucilAir™-HF MucilAir™-HF Pool of Donors MucilAir™-HF-Asthma MucilAir™-HF Allergic Rhinitis MucilAir™-HF-Smoker MucilAir™-HF-COPD MucilAir™-HF-CF

EP11MD EP12MP EP13MD EP14MD EP15MD EP16MD EP17MD

Description Ref # Description Ref #

Sm

all

Air

™

SmallAir™ SmallAir™-Asthma SmallAir™-Allergic Rhinitis SmallAir™-Smoker SmallAir™-COPD SmallAir™-CF

EP21SA EP23SA EP24SA EP25SA EP26SA EP27SA

SmallAir™-HF SmallAir™-HF-Asthma SmallAir™-HF-Allergic Rhinitis SmallAir™-HF-Smoker SmallAir™-HF-COPD SmallAir™-HF-CF

EP31SA EP33SA EP34SA EP35SA EP36SA EP37SA

MucilAir™ culture medium (125mL) MucilAir™ culture medium (500mL)

EP40MM EP41MM

SmallAir™ culture medium (125mL) SmallAir™ culture medium (500mL)

EP42SA EP43SA

Primary Human Cells & Extracts

Pri

mary

Hu

ma

n C

ells

Available from Nose, Trachea,

Bronchi and Small Airways

hAEC / hSAEC hAEC / hSAEC - Asthma hAEC / hSAEC - Allergic rhinitis hAEC / hSAEC - Smoker hAEC / hSAEC - COPD hAEC / hSAEC - CF

Human Pulmonary Fibroblasts

Ref #

EP51AB / EP61SA EP53AB / EP63SA EP54AB / EP64SA EP55AB / EP65SA EP56AB / EP66SA EP57AB / EP67SA

EP91AB

hAEC Culture Medium (500mL) hSAEC Culture Medium (500mL)

EP44AM EP45SA

Ce

lls

&

Tis

su

es

Ex

tra

cts

Mucin, Cell Pellet, Histology, ADN, ARN or protein extract, etc.

On Request Please Contact Us

Epithelix Sàrl 18, Chemin des Aulx – CH-1228 Plan-les-Ouates – Genève – Switzerland

Tel: +41 (0) 22 794 65 15 / Fax: +41 (0) 22 794 65 17 epithelix@epithelix.com – www.epithelix.com

Currently available in vitro Testing Services

Contract us to perform the following Acute, Long-term and Chronic in vitro studies:

Cilia Beating Frequency & Mucociliary Clearance Monitoring

Do your compounds increase or decrease the Ciliary Beat Frequency (CBF) or impact the

mucociliary clearance (MCC)? Is it increasing/decreasing or desynchronizing the cilia beating?

The effects of your compounds can be assessed in real time or

high throughput in a non-invasive manner on MucilAir™ and

SmallAir™. CBF is monitored with digital video files of motile

ciliated respiratory epithelial cells through a high-speed digital

video recorder. The mucociliary clearance is monitored using a

fully automated video-microscopy based setup. Microbeads of 30

microns are seeded onto the apical surface, then are then tracked

using specialized software allowing the calculation of their

velocities.

Cilia Frequency Distribution Microbeads tracking

Comparison of particles velocities between

MucilAir™-Normal and MucilAir™-CF

Normal CF

Epithelix Sàrl 18, Chemin des Aulx – CH-1228 Plan-les-Ouates – Genève – Switzerland

Tel: +41 (0) 22 794 65 15 / Fax: +41 (0) 22 794 65 17 epithelix@epithelix.com – www.epithelix.com

0

100

200

300

400

500

1.E+02

1.E+05

1.E+08

1.E+11

1.E+14

1.E+17

24H 48H 72H 96H

TEER

[Ω

.cm

2 ]

[CFU

/ M

uci

lAir

™]

Pseudomonas aeruginosa growth and TEER on MucilAir™

TEER w/o Meronem TEER with Meronem

CFU w/o Meronem CFU with Meronem

A relevant and reliable in vitro cell model for testing

novel antivirals (new)

A panel of clinical rhinovirus (RV), respiratory enterovirus (EV), influenza virus (Flu), respiratory

syncytial virus (RSV) and coronavirus (HCoV) specimens are all capable of productive infection in

MucilAir™ (Essaidi-Laziosi et al., JACI, 2017). Rupintrivir and Oseltamivir efficiently inhibit the

replication of rhinoviruses and influenza viruses, respectively. Thus, MucilAir™ is a relevant, reliable,

and convenient tool for testing novel anti-viral drugs against the respiratory viruses, including the most

challenging ones.

An in vitro platform to evaluate novel antibiotics against

respiratory bacterial infections (new)

Respiratory bacterial infections cause mild to severe diseases worldwide. To develop new therapies,

relevant human models are mandatory. MucilAir™ and SmallAir™ replicate not only the barrier

function, but also the innate defense mechanisms of human airway epithelium including mucus

production, mucociliary clearance, production and secretion of anti-microbial peptides. Many end-

points like Trans Epithelial Electrical Resistance (TEER) and bacterial growth (Colony Forming Unit:

CFU) can be monitored all along the infection to predict prevention of (i) cytotoxicity, (ii) disruption

of barrier function and (iii) impairment of cilia activity.

Available clinical strains for drug screening

Available strains for drug screening assay

Time course of replication of respiratory viruses